Coding Test score at Day 42," and that "[b]ased on the data, [Sage Therapeutics] does not plan any further development of dalzanemdor (SAGE-718) in PD." On this news, the price of Sage Therapeutics ...
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...
the primary endpoint of Wechsler Adult Intelligence Scale Fourth Edition-IV [WAIS-IV] Coding Test score compared to placebo at day 42 was not met with statistical significance. With this data on ...